Abstract: The present invention concerns the use of plasminogen, a variant thereof, or an analog thereof having a plasminogen activity, for the prevention or treatment of a condition or a disease that is characterized with an increased PAI-1 level. The conditions and diseases that are characterized with an increased PAI-1 level, are regrouped within two categories: the diseases associated with an impaired vascular or tissue remodeling capacity, and the metabolic and hormonal disorders associated with an increased PAI-1 level.
Type:
Grant
Filed:
June 22, 2018
Date of Patent:
November 28, 2023
Assignee:
PROMETIC BIOTHERAPEUTICS, INC.
Inventors:
Lyne Gagnon, Brigitte Grouix, Pierre Laurin
Abstract: Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilising agent and has a pH of about 3.0 to about 10.0. In another embodiment, the composition contains an amount of particles in suspension equal to or greater than 10 ?m which is lower than 6000 particles per 100 ml, and preferably lower than 2000 particles per 100 ml. Uses of these compositions as a medicament is contemplated. Various therapeutic uses of these pharmaceutical compositions is also contemplated.
Type:
Grant
Filed:
December 22, 2020
Date of Patent:
April 25, 2023
Assignee:
PROMETIC BIOTHERAPEUTICS, INC.
Inventors:
Davida Blackman, Stacy Plum, William Garzon-Rodriguez, Martin Robitaille, Betty Yu
Abstract: Subjects of the invention are a method of plasminogen supplementation in a plasminogen-deficient subject, and method for the treatment of plasminogen-deficiency in a plasminogen-deficient subject. These methods comprise administering to the plasminogen-deficient subject a dose of plasminogen, and more particularly Glu-plasminogen, for increasing the subject plasminogen activity level by at least about 1%, and more particularly by at least 10%, of the normal plasminogen activity and for maintaining the plasminogen activity level over a supplementation period or a treatment period. The plasminogen-deficient subject of the present invention may suffer from Type-I, Type-II plasminogen-deficiency or an acquired deficiency.
Type:
Grant
Filed:
November 3, 2016
Date of Patent:
April 5, 2022
Assignee:
PROMETIC BIOTHERAPEUTICS, INC.
Inventors:
Martin Robitaille, Karen Thibaudeau, Pierre Laurin, Stacy Plum
Abstract: Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilising agent and has a pH of about 3.0 to about 10.0. In another embodiment, the composition contains an amount of particles in suspension equal to or greater than 10 ?m which is lower than 6000 particles per 100 ml, and preferably lower than 2000 particles per 100 ml. Uses of these compositions as a medicament is contemplated. Various therapeutic uses of these pharmaceutical compositions is also contemplated.
Type:
Grant
Filed:
August 28, 2019
Date of Patent:
January 26, 2021
Assignee:
PROMETIC BIOTHERAPEUTICS, INC.
Inventors:
Davida Blackman, Stacy Plum, William Garzon-Rodriguez, Martin Robitaille, Betty Yu
Abstract: Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilizing agent and has a pH of about 3.0 to about 10.0. In another embodiment, the composition contains an amount of particles in suspension equal to or greater than 10 ?m which is lower than 6000 particles per 100 ml, and preferably lower than 2000 particles per 100 ml. Uses of these compositions as a medicament is contemplated. Various therapeutic uses of these pharmaceutical compositions is also contemplated.
Type:
Grant
Filed:
December 18, 2015
Date of Patent:
October 15, 2019
Assignee:
PROMETIC BIOTHERAPEUTICS, INC.
Inventors:
Davida Blackman, Stacy Plum, William Garzon-Rodriguez, Martin Robitaille, Betty Yu